Andrew Shutterly, the Acting Chief Financial Officer of Altimmune, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC on July 1, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Shutterly's direct ownership of 10,113 shares of common stock and various derivative securities, including stock options and restricted stock units (RSUs). The stock options have exercise prices ranging from $4.48 to $12.88 and vesting periods extending up to 2034. The RSUs are set to vest in annual installments through 2027, contingent upon Shutterly's continued service. This filing provides transparency into the holdings of Altimmune's executives and is a routine disclosure for investors monitoring insider transactions.

Andrew Shutterly, the Acting Chief Financial Officer of Altimmune, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC on July 1, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Shutterly's direct ownership of 10,113 shares of common stock and various derivative securities, including stock options and restricted stock units (RSUs). The stock options have exercise prices ranging from $4.48 to $12.88 and vesting periods extending up to 2034. The RSUs are set to vest in annual installments through 2027, contingent upon Shutterly's continued service. This filing provides transparency into the holdings of Altimmune's executives and is a routine disclosure for investors monitoring insider transactions.